COMPLETEDPHASE2

Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

NCT00018343•US Department of Veterans Affairs

Summary

This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.

Eligibility

Age

50 - 90 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Post menopausal women with alzheimer's disease
•free of any major medical or neurological disease,
•medically safe to be treated with estrogen.

Locations (1)

VA Puget Sound Health Care System

Lakewood, Washington, United States

Key Dates

Start Date

April 1, 1998

Completion Date

March 1, 2001

Last Updated

January 21, 2009

Conditions

Alzheimer's Disease

Interventions

estrogen

DRUG

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PHASE2